x 

0 Activities
0 Activities
    • No Saved Activities

Credits2

  2. Home
  3. Credits2
  4. Format
  5. Webinar

 

Search

Page 4 of 4
Results 226 - 294 of 294
rePlace2
Nontuberculous Mycobacteria Case 2: Alan
rePlace2
Treatment Challenges with MAC Lung Disease
rePlace2
Nontuberculous Mycobacteria: Summary
rePlace2
Treatment Challenges with MABC Lung Disease
rePlace2
Nontuberculous Mycobacteria Case 1: Maria
rePlace2
NTM – To Treat or Not to Treat
rePlace2
Goals of NTM Treatment
rePlace2
Guideline-recommended Treatments for NTM
rePlace2
Diagnosis of NTM
rePlace2
Factors Associated with Respiratory Involvement in NTM
rePlace2
Most Common Species in NTM Lung Disease
rePlace2
Nontuberculous Mycobacteria: Introduction and Epidemiology
atopic-derm4
Atopic Dermatitis: Putting it Together (Dermatology)
atopic-derm3
Atopic Dermatitis: Putting it Together (Primary Care)
atopic-derm2 copy
Atopic Dermatitis: Recent and Emerging Therapies
atopic-derm1
An Introduction to Atopic Dermatitis
No image set
Achieving Better Control of Severe Asthma
biosims-archmed icon23
Top Questions about Biosimilars in Dermatology
biosims-archmed icon1
Top Questions about Biosimilars in Gastroenterology
biosims-archmed icon2
Top Questions about Biosimilars in Rheumatology
biosims-archmed icon
Top Questions about Biosimilars in Hematology/Oncology
biosims-gastro2
Biosimilars and Patients with Inflammatory Bowel Disease
biosims-gastro1
Biosimilars: The New Era of Gastroenterology Management Considerations
psoriasis-nurse
Psoriasis Management Considerations: What Would You Do?
psoriasis-case2
Psoriasis: Three Case Studies in the Primary Care Setting
psoriasis-case1
Cindy Has a Complex Case of Psoriasis
No image set
Optimizing Patient Outcomes in IPF
No image set
Understanding IPF as a Part of the Overall Scope of ILD
aims icon-target
Targeting B-cells in Primary Progressive MS (PPMS)
aims icon-comorb
Comorbidities and Selection of DMTs
aims icon-gut
The Gut Microbiota in MS
aims icon-early
Early MS: Induction Therapy and Escalation Strategies
aims icon-vitamin
Vitamin D: Modifiable Risk Factor and its Role in the Management of Patients with MS
No image set
UIP, IPF, NSIP, CHP: Making Sense of the Letters
t2diabetes-louise
Getting to Goal Can Be Difficult: Louise
t2diabetes-brian
Getting to Goal Can Be Difficult: Brian
IL-rheum-case3
Considering Biosimilars in Patients Failing their Initial Biologic
IL-rheum-case2
When to Switch? Biologically Experienced Patients with Spondyloarthritis
IL-rheum-case1
Innovator or Biosimilar for a Patient with Rheumatoid Arthritis
IL-gastro-case3
Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?
IL-gastro-case2
Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic
IL-gastro-case1
Innovator or Biosimilar for a Patient with Ulcerative Colitis?
IL-derm-case3
Switching Between Biologics: Is a Biosimilar an Option?
IL-derm-case2
When to Switch? Biologically Experienced Psoriasis Patients
IL-derm-case1
Innovator or Biosimilar for a Patient with Psoriasis
IL-fund-case4
Interchangeability and Pharmacy-Level Substitution
IL-fund-case3
FDA Criteria: Biosimilar Approval, Manufacturing, & Naming
IL-fund-case2
What is the Difference Between a Biosimilar and a Generic?
IL-fund-case1
What is a Biologic?
No image set
New Strides in EGFR Inhibition for Non–Small Cell Lung Cancer
No image set
Pete - Work-Up of a Patient with Right Upper Lobe Mass and Metastases
No image set
Carl - High Suspicion of Lung Cancer: Setting the Stage with a Good Biopsy
biosims-full
Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics
biosims-green5
Are You Ready to Use Biosimilars in Your Practice?
biosims-full3
Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?
biosims-green3
Pharmacovigilance and Biosimilars: Any Special Considerations?
biosims-full5
Interchangeability and Biosimilars: What will this Mean for Clinical Practice?
biosims-green8
Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?
biosims-full7
Biosimilars: As Safe and Effective as the Reference Product?
biosims-green
Drift and the Manufacturing of Biologics: What is it and Does it Matter?
No image set
Radiologic Features of IPF
No image set
Gwen: A lawyer with a history of MI has a dry cough and trouble with stairs
No image set
Elizabeth: Loves the outdoors but bothered by persistent cough and GERD
No image set
Toni: Too tired to continue teaching and experiencing painful heartburn
biosims-full8
Biosimilars in Clinical Practice: Interchangeability and Extrapolation
9529-00028
Approach to Genetic Testing in Myopathies
9529-00014
Molecular Diagnosis of Limb-Girdle Muscle Weakness
No image set
Treatment Dilemmas Case Study: Harrison
No image set
A New Era in IPF: Trials and Treatments
Page 4 of 4

Search